• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

证据与价值:对决策的影响——EVIDEM框架及其潜在应用

Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.

作者信息

Goetghebeur Mireille M, Wagner Monika, Khoury Hanane, Levitt Randy J, Erickson Lonny J, Rindress Donna

机构信息

BioMedCom Consultants Inc, 1405 Transcanada Highway, Suite 310, Dorval, Québec H9P 2V9, Canada.

出版信息

BMC Health Serv Res. 2008 Dec 22;8:270. doi: 10.1186/1472-6963-8-270.

DOI:10.1186/1472-6963-8-270
PMID:19102752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2673218/
Abstract

BACKGROUND

Healthcare decisionmaking is a complex process relying on disparate types of evidence and value judgments. Our objectives for this study were to develop a practical framework to facilitate decisionmaking in terms of supporting the deliberative process, providing access to evidence, and enhancing the communication of decisions.

METHODS

Extensive analyses of the literature and of documented decisionmaking processes around the globe were performed to explore what steps are currently used to make decisions with respect to context (from evidence generation to communication of decision) and thought process (conceptual components of decisions). Needs and methodologies available to support decisionmaking were identified to lay the groundwork for the EVIDEM framework.

RESULTS

A framework was developed consisting of seven modules that can evolve over the life cycle of a healthcare intervention. Components of decision that could be quantified, i.e., intrinsic value of a healthcare intervention and quality of evidence available, were organized into matrices. A multicriteria decision analysis (MCDA) Value Matrix (VM) was developed to include the 15 quantifiable components that are currently considered in decisionmaking. A methodology to synthesize the evidence needed for each component of the VM was developed including electronic access to full text source documents. A Quality Matrix was designed to quantify three criteria of quality for the 12 types of evidence usually required by decisionmakers. An integrated system was developed to optimize data analysis, synthesis and validation by experts, compatible with a collaborative structure.

CONCLUSION

The EVIDEM framework promotes transparent and efficient healthcare decisionmaking through systematic assessment and dissemination of the evidence and values on which decisions are based. It provides a collaborative framework that could connect all stakeholders and serve the healthcare community at local, national and international levels by allowing sharing of data, resources and values. Validation and further development is needed to explore the full potential of this approach.

摘要

背景

医疗保健决策是一个复杂的过程,依赖于不同类型的证据和价值判断。本研究的目的是开发一个实用框架,以促进决策制定,包括支持审议过程、提供获取证据的途径以及加强决策沟通。

方法

对全球范围内的文献和记录在案的决策过程进行了广泛分析,以探索目前在决策过程中针对背景(从证据生成到决策沟通)和思维过程(决策的概念组成部分)所采用的步骤。确定了支持决策的需求和可用方法,为EVIDEM框架奠定基础。

结果

开发了一个由七个模块组成的框架,该框架可在医疗保健干预的生命周期内不断演变。可以量化的决策组成部分,即医疗保健干预的内在价值和可用证据的质量,被整理成矩阵。开发了多标准决策分析(MCDA)价值矩阵(VM),以纳入目前决策中考虑的15个可量化组成部分。开发了一种方法来综合VM每个组成部分所需的证据,包括通过电子方式获取全文源文件。设计了一个质量矩阵,以量化决策者通常所需的12种证据类型的三个质量标准。开发了一个集成系统,以优化专家进行的数据分析、综合和验证,该系统与协作结构兼容。

结论

EVIDEM框架通过系统评估和传播决策所依据的证据和价值观,促进透明和高效的医疗保健决策。它提供了一个协作框架,可以连接所有利益相关者,并通过允许共享数据、资源和价值观,为地方、国家和国际层面的医疗保健社区服务。需要进行验证和进一步开发,以探索这种方法的全部潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/229b16a086b7/1472-6963-8-270-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/57f2427586ed/1472-6963-8-270-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/351a9d96819b/1472-6963-8-270-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/810cf4ba11a2/1472-6963-8-270-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/dbf0a4ae0d00/1472-6963-8-270-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/8fe01e875ad0/1472-6963-8-270-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/08ba7cf3889d/1472-6963-8-270-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/e0a9af624e07/1472-6963-8-270-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/229b16a086b7/1472-6963-8-270-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/57f2427586ed/1472-6963-8-270-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/351a9d96819b/1472-6963-8-270-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/810cf4ba11a2/1472-6963-8-270-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/dbf0a4ae0d00/1472-6963-8-270-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/8fe01e875ad0/1472-6963-8-270-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/08ba7cf3889d/1472-6963-8-270-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/e0a9af624e07/1472-6963-8-270-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b474/2673218/229b16a086b7/1472-6963-8-270-8.jpg

相似文献

1
Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.证据与价值:对决策的影响——EVIDEM框架及其潜在应用
BMC Health Serv Res. 2008 Dec 22;8:270. doi: 10.1186/1472-6963-8-270.
2
Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.将卫生技术评估 (HTA) 与多准则决策分析 (MCDA) 相结合:在加拿大,对公共支付方进行覆盖决策的 EVIDEM 框架进行现场测试。
BMC Health Serv Res. 2011 Nov 30;11:329. doi: 10.1186/1472-6963-11-329.
3
Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.南非宫颈癌筛查检测覆盖的多准则决策分析(MCDA)框架的现场测试。
Cost Eff Resour Alloc. 2012 Feb 29;10(1):2. doi: 10.1186/1478-7547-10-2.
4
Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.结合多准则决策分析、伦理学和卫生技术评估:将 EVIDEM 决策框架应用于特纳综合征患者的生长激素治疗。
Cost Eff Resour Alloc. 2010 Apr 8;8:4. doi: 10.1186/1478-7547-8-4.
5
Can reflective multicriteria be the new paradigm for healthcare decision-making? The EVIDEM journey.反思性多标准能否成为医疗保健决策的新范式?EVIDEM之旅。
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):54. doi: 10.1186/s12962-018-0116-9. eCollection 2018.
6
From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking.从疗效到公平:资源配置和医疗保健决策的决策标准文献综述。
Cost Eff Resour Alloc. 2012 Jul 18;10(1):9. doi: 10.1186/1478-7547-10-9.
7
Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.将健康技术评估(HTA)与多准则决策分析(MCDA)相结合,以实现高效的医疗保健决策:将 EVIDEM 框架应用于药品评估。
Med Decis Making. 2012 Mar-Apr;32(2):376-88. doi: 10.1177/0272989X11416870. Epub 2011 Oct 10.
8
DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.加泰罗尼亚的药物评估与决策:基于多准则决策分析(MCDA)的孤儿药物方法学框架的开发与验证。
Int J Technol Assess Health Care. 2017 Jan;33(1):111-120. doi: 10.1017/S0266462317000149. Epub 2017 Apr 24.
9
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
10
Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.影响中国公立医院药品采购决策制定框架的因素:五种二肽基肽酶-4(DPP-4)抑制剂的价值评估。
BMC Health Serv Res. 2021 Aug 12;21(1):807. doi: 10.1186/s12913-021-06827-0.

引用本文的文献

1
The relative importance of severity and rarity criteria in health resource allocation: an umbrella review.严重程度和罕见程度标准在卫生资源配置中的相对重要性:伞式审查。
Int J Technol Assess Health Care. 2024 Nov 14;40(1):e54. doi: 10.1017/S0266462324004653.
2
Strategies to optimise the health equity impact of digital pain self-reporting tools: a series of multi-stakeholder focus groups.优化数字疼痛自我报告工具对健康公平影响的策略:一系列多利益相关者焦点小组。
Int J Equity Health. 2024 Nov 11;23(1):233. doi: 10.1186/s12939-024-02299-w.
3
Establishment of a value assessment framework for orphan medicinal products in China.

本文引用的文献

1
6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.6-STEPPPs:一个用于促进临床医生参与公平决策以资助新型癌症药物的模块化工具。
J Oncol Pract. 2008 Jan;4(1):2-7. doi: 10.1200/JOP.0812001.
2
The AMCP format for formulary submissions version 2.1.药品目录提交的AMCP格式第2.1版。
J Manag Care Pharm. 2005 Jun;11(5 Suppl B):vi-xvi, 1-29, 1-4.
3
Decision maker views on priority setting in the Vancouver Island Health Authority.决策者对温哥华岛卫生局优先事项设定的看法。
建立中国孤儿药的价值评估框架。
Orphanet J Rare Dis. 2024 Oct 20;19(1):390. doi: 10.1186/s13023-024-03393-6.
4
An innovative tool to prioritize the assessment of investigational COVID-19 therapeutics: A pilot project.一种用于确定新型冠状病毒肺炎(COVID-19)研究性治疗评估优先级的创新工具:一个试点项目。
Can Commun Dis Rep. 2024 Oct 3;50(10):357-364. doi: 10.14745/ccdr.v50i10a04. eCollection 2024 Oct.
5
A multiple criteria decision analysis to establish the use cases and candidate point of care tests to enter into a platform trial of multiple diagnostic point of care tests in the prehospital environment.一项多标准决策分析,以确定用例和候选即时检验项目,用于在院前环境中开展多项诊断性即时检验的平台试验。
NIHR Open Res. 2024 Jul 23;4:29. doi: 10.3310/nihropenres.13580.2. eCollection 2024.
6
Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis.评价 vonoprazan 和 tegoprazan 治疗中国医疗保健中胃食管反流病的效果:基于 EVIDEM 框架的分析。
BMC Gastroenterol. 2024 Jun 20;24(1):208. doi: 10.1186/s12876-024-03297-6.
7
Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis.基于血液神经丝轻链的价值贡献作为多发性硬化症的生物标志物的多准则决策分析。
Front Public Health. 2024 Apr 22;12:1397845. doi: 10.3389/fpubh.2024.1397845. eCollection 2024.
8
From bench to policy: a critical analysis of models for evidence-informed policymaking in healthcare.从基础研究到政策制定:医疗保健中循证决策模型的批判性分析。
Front Public Health. 2024 Mar 26;12:1264315. doi: 10.3389/fpubh.2024.1264315. eCollection 2024.
9
Design of a multiple criteria decision analysis framework for prioritizing high-impact health technologies in a regional health service.用于对区域卫生服务中具有高影响力的卫生技术进行优先排序的多标准决策分析框架设计
Int J Technol Assess Health Care. 2024 Apr 5;40(1):e21. doi: 10.1017/S0266462324000205.
10
Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop.纳入获益-风险评估的优效性、等效性和非劣效性临床试验的恰当设计和报告:包含专家研讨会的 BRAINS 研究。
Health Technol Assess. 2023 Oct;27(20):1-58. doi: 10.3310/BHQZ7691.
Cost Eff Resour Alloc. 2008 Jul 21;6:13. doi: 10.1186/1478-7547-6-13.
4
Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity.三种评估经济评估质量的工具比较:肥胖症手术治疗经济评估的实际操作
Int J Technol Assess Health Care. 2008 Summer;24(3):318-25. doi: 10.1017/S0266462308080422.
5
The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.英国国家卫生与临床优化研究所(NICE)对成本效益的运用:并非(尚未成为)审慎程序的典范。
J Med Ethics. 2008 Jul;34(7):534-9. doi: 10.1136/jme.2007.021683.
6
Priority setting in practice: what is the best way to compare costs and benefits?实践中的优先级设定:比较成本与效益的最佳方法是什么?
Health Econ. 2009 Apr;18(4):467-78. doi: 10.1002/hec.1380.
7
"Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government.“培养对证据的敏锐洞察力”:州政府循证卫生政策制定的促进因素与阻碍因素
Milbank Q. 2008 Jun;86(2):177-208. doi: 10.1111/j.1468-0009.2008.00519.x.
8
Optimizing the use of prescription drugs in Canada through the Common Drug Review.通过通用药品审查优化加拿大处方药的使用。
CMAJ. 2008 Feb 12;178(4):432-5. doi: 10.1503/cmaj.070713.
9
Moving from opacity to transparency in pharmaceutical policy.推动药品政策从不透明走向透明。
CMAJ. 2008 Feb 12;178(4):428-31. doi: 10.1503/cmaj.070799.
10
The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes.未经治疗的预后对医生和患者资源分配决策的影响及其与新药推荐流程的相关性。
Br J Clin Pharmacol. 2008 Feb;65(2):224-9. doi: 10.1111/j.1365-2125.2007.02996.x.